What it sells
Gen-AI Designed Enzymes for Pharmaceutical Innovation
Business model breakdown
Trigger: what makes them buy now?
Low enzyme activity or costly multi-step chemical synthesis of a drug (e.g. 17 chemical steps) that enzymatic conversion could replace.
Workflow: what inputs become what output?
Customer supplies a target reaction or enzyme with low activity; Pando sources/engineers enzymes with AI plus a wet-lab screening platform, delivers variants with FTO and no prior art.
Economics: what it saves and how it charges
Custom service/program deals (biocatalysis, DNA-modifying enzyme programs) plus catalog enzyme products; claims cost reduction of 50% and $24M new profit in case studies.
Distribution: how it reaches customers
Direct BD with founders, conferences (CPHI, ASHG, AMP) and LinkedIn; contact-us form.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2023 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.